References
1. Schernthaner G., Currie C.J., Schernthaner G.-H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013; 36 (Suppl 2): S 155-61. DOI: https://doi.org/10.2337/dcS 13-2031
2. Perdigoto A.L., Young L.H., Inzucchi S.E. Pioglitazone and cardiovascular risk reduction: time for a second look? Cardiovasc Endocrinol. 2017; 6 (2): 55-61. DOI: https://doi.org/10.1097/XCE.0000000000000110
3. Eldor R., DeFronzo R.A., Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care. 2013; 36 (Suppl 2): S162-74. DOI: https://doi.org/10.2337/dcS13-2003
4. Ryder R.E., Defronzo R.A. Rehabilitation of pioglitazone: 2. Br J Diabetes. 2015; 15 (2): 46-9. DOI: http://dx.doi.org/10.15277/bjdvd.2015.021
5. Nesti L., Tricò D., Mengozzi A., Natali A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021; 20 (1): 109. DOI: https://doi.org/10.1186/s12933-021-01294-7
6. Triplitt C., Cersosimo E., DeFronzo R.A. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag. 2010; 6: 671-90. DOI: https://doi.org/10.2147/vhrm.s4852
7. DeFronzo R.A., Inzucchi S., Abdul-Ghani M., Nissen S.E., et al. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019; 16 (2): 133-43. DOI: https://doi.org/10.1177/1479164118825376
8. Ahn C.H., Lim S. Effects of thiazolidinedione and new antidiabetic agents on stroke. J Stroke. 2019; 21 (2): 139-50.
9. Di Pino A., DeFronzo R.A. Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocr Rev. 2019; 40 (6): 1447-67.
10. Ryder R.E.J., DeFronzo R.A. Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? 1. Br J Diabetes. 2020; 20 (1): 5-8.
11. DeFronzo R.A., Chilton R., Norton L., Clarke G., et al. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. Diabetes Obes Metab. 2016; 18 (5): 454-62. DOI: https://doi.org/10.1111/dom.12652
12. Sumida Y., Yoneda M., Tokushige K., Kawanaka M., et al. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Int J Mol Sci. 2020; 21 (6): 1907. DOI: https://doi.org/10.3390/ijms21061907
13. Cusi K., Orsak B., Bril F., Lomonaco R., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016; 165 (5): 305-15. DOI: https://doi.org/10.7326/M15-1774
14. Nesto R.W., Bell D., Bonow R.O., Fonseca V., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004; 27 (1): 256-63. DOI: https://doi.org/10.2337/diacare.27.1.256
15. Satirapoj B., Watanakijthavonkul K., Supasyndh O. Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: a randomized controlled trial. PLoS One. 2018; 13 (10): e0206722. DOI: https://doi.org/10.1371/journal.pone.0206722
16. Tomlinson B., Chan P., Lam C.W.K. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2022; 23 (1): 29-42. DOI: https://doi.org/10.1080/14656566.2021.1985465
17. Rosenstock J., Inzucchi S.E., Seufert J., Fleck P.R., et al. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010; 33 (11): 2406-8. DOI: https://doi.org/10.2337/dc10-0159
18. DeFronzo R.A., Burant C.F., Fleck P., Wilson C., et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97 (5): 1615-22. DOI: https://doi.org/10.1210/jc.2011-2243
19. Kim J.M., Kim S.S., Kim J.H., et al. Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy: A randomized, open-label, multicenter, parallel-controlled study. Diabetes Metab J. 2020; 44 (1): 67-77. DOI: https://doi.org/10.4093/dmj.2018.0274
20. Van Raalte D.H., van Genugten R.E., Eliasson B., et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014; 170 (4): 565-74. DOI: https://doi.org/10.1530/EJE-13-0639
21. Eliasson B., Möller-Goede D., Eeg-Olofsson K., et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012; 55 (4): 915-25. DOI: https://doi.org/10.1007/s00125-011-2447-3